| アブストラクト | INTRODUCTION: Hearing loss can have a negative impact on communication, with significant vocational, educational, and social consequences. Drugs are one of the causes of hearing loss in children. OBJECTIVES: The objective of our study was to describe drug-induced hearing loss in the pediatric population. METHODS: Reports of hearing loss from 1985 to December 2019 in the pediatric population (< 18 years) were extracted from the French PharmacoVigilance Database (FPVD). We performed a retrospective and descriptive analysis of adverse drug reaction (ADR) reports. RESULTS: A total of 70 ADR reports were identified among the 51,216 reports registered in the FPVD, 37 involving adolescents (12-17 years, 52.9%), 28 children (2-11 years, 40.0%), and 5 infants (28 days-23 months, 7.1%). Overall, 40 reports (57.1%) involved girls. A total of 56 reports (80.0%) were "serious." The most frequent hearing disorders were deafness (n = 31, 44.3%) and hypoacusis (n = 22, 31.4%). Suspected drugs (ATC 5th level) were amikacin (n = 11, 15.7%), cisplatin (n = 11, 15.7%), doxorubicin (n = 4, 5.7%), vincristine (n = 4, 5.7%), clarithromycin (n = 4, 5.7%), ceftriaxone (n = 3, 4.3%), isotretinoin (n = 3, 4.3%), and vancomycin (n = 3, 4.3%). CONCLUSIONS: This study shows that about three out of four cases of drug-induced hearing loss in the pediatric population were "serious". It also underlines the under-reporting of these ADRs and the importance of strengthening hearing monitoring in children during and long after drug exposure. |
|---|
| ジャーナル名 | Paediatric drugs |
|---|
| 投稿日 | 2020/11/18 |
|---|
| 投稿者 | Gainville, Adrien; Rousseau, Vanessa; Kaguelidou, Florentia; Gervoise, Marie Boyer; Michot, Joelle; Pizzoglio-Bellaudaz, Veronique; Chebane, Leila; Weckel, Alexandra; Montastruc, Jean-Louis; Durrieu, Genevieve |
|---|
| 組織名 | Service de Pharmacologie Medicale et Clinique, Centre Regional de;Pharmacovigilance, Pharmacoepidemiologie et Informations sur le Medicament,;INSERM U 1027, CIC INSERM 1436, Centre Hospitalier Universitaire et Faculte de;Medecine de Toulouse, France, 37 Allees Jules Guesde, 31000, Toulouse, France.;Centre d'Investigation Clinique, INSERM CIC1426, Hopital Robert Debre, 48,;boulevard Serurier, 75019, Paris, France.;Service de pharmacologie clinique et pharmacovigilance, centre regional de;pharmacovigilance Marseille Provence Corse, hopital Sainte-Marguerite, Hopitaux;de Marseille, 13009, Marseille, France.;Centre Regional de Pharmacovigilance, Saint Antoine Hopital (APHP), Paris,;France.;Service Hospitalo-Universitaire de Pharmacotoxicologie, Centre de;Pharmacovigilance, Hospices Civils de Lyon, CHU-Lyon, Lyon, France.;Service d'ORL pediatrique, Centre Hospitalier Universitaire de Toulouse,;Toulouse, France.;genevieve.durrieu@univ-tlse3.fr. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/33200354/ |
|---|
